Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA

Lancet

Volumn 354, Issue 9183, 1999, Pages 975-978

  Makridakis, Nick M ^a   Ross, Ronald K ^a   Pike, Malcolm C ^a   Crocitto, Laura E ^a   Kolonel, Laurence N ^a   Pearce, C Leigh ^a   Henderson, Brian E ^a   Reichardt, Jürgen K V ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANDROSTANOLONE; COMPLEMENTARY DNA; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; THREONINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; ETHNIC GROUP; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NEGRO; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; TESTOSTERONE METABOLISM; UNITED STATES;

EID: 0033581453     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)11282-5     Document Type: Article

References (24)

1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1998. CA Cancer J Clin. 48:1998;6-29.
2. Black R.J., Bray F., Ferlay J., Parkin D.M. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer. 73:1997;1075-1107.
3. Huggins C., Hodges C.V. Studies on prostatic cancer. Cancer Res. 1:1941;293-297.
4. Henderson B.E., Ross R.K., Pike M.C., Casagrande J.T. Endogenous hormones as a major factor in human cancer. Cancer Res. 42:1982;3232-3239.
5. Ross R.K., Pike M.C., Coetzee G.A.et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res. 58:1998;4497-4504.
6. Ross R.K., Bernstein L., Lobo R.A.et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 339:1992;887-889.
7. Makridakis N., Ross R.K., Pike M.C.et al. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res. 57:1997;1020-1022.
8. Kolonel, L.N., Henderson, B.E., Hankin, J.H. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol (in press).
9. Andriole G.L., Catalona W.J. The diagnosis and treatment of prostate cancer. Annu Rev Med. 42:1991;9-15.
10. Montie J.E., Pienta K.J., Pontes P.E. Staging systems and prognostic factors for prostate cancer. Vogelzang N.J. Comprehensive textbook of genitourinary oncology. 1997;712-722 Williams and Wilkins, Baltimore.
11. Montie J.E. 1992 staging system for prostate cancer. Semin Urol. 11:1993;10-13.
12. Miettinen O.S. Proportion of disease caused by or prevented by given exposure, trait or intervention. Am J Epidemiol. 99:1974;325-332.
13. Ausubel, F.M., Brent, R., Kingston, R.E., et al, eds. Current protocols in molecular biology. New York: Wiley & Sons, 1995.
14. Wigley W.C., Prihoda J.S.et al. Natural mutagenesis of the human steroid 5α-reductase 2 isozyme. Biochemistry. 33:1994;1265-1270.
15. Stoner E. 5α-reductase inhibitors/finasteride. Prostate. 6:1996;82-87.
16. Reichardt J.K.V., Makridakis N., Henderson B.E., Yu M.C., Pike M.C., Ross R.K. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 55:1995;3973-3975.
17. Davis D.L., Russell D.W. Unusual length polymorphism in human steroid 5α-reductase type 2 gene (SRD5A2). Hum Mol Genet. 2:1993;820.
18. Kantoff P.W., Febbo P.G., Giovannucci E.et al. A polymorphism of the 5α-reductase gene and its association with prostate cancer: a case-control analysis. Cancer Epidem Biomark Prev. 6:1997;189-192.
19. Thigpen A.E., Davis D.L., Milatovich A.et al. Molecular genetics of steroid 5α-reductase 2 deficiency. J Clin Invest. 90:1992;799-809.
20. Carter B.S., Beaty T.H., Steinberg G.D., Childs B., Walsh P.C. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA. 89:1992;3367-3371.
21. Smith J.R., Freize D., Carpten J.D.et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science. 274:1996;1371-1374.
22. McIndoe R.A., Stanford J.L., Gibbs M.et al. Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25. Am J Hum Genet. 61:1997;347-353.
23. Berthon P., Valeri A., Cohen-Akenine A.et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet. 62:1998;1416-1424.
24. Xu J., Meyers D., Freize D.et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet. 20:1998;175-179.